论文部分内容阅读
目的:观察小剂量多西紫杉醇每周给药对局部晚期鼻咽癌患者的放疗增敏并了解其毒副反应情况。方法:入选临床分期Ⅲ和ⅣA期鼻咽癌患者72例,随机分为观察组和对照组。观察组每周给药多西紫杉醇1次,40 m g+放疗。对照组采用单纯放疗。放疗方法:两组均用6mV直线加速器,采用低溶点铅档块技术,鼻咽原发灶肿瘤量为每7~8周6 8~7 6,颈部淋巴结转移灶肿瘤量为每6~7周6 0~7 0。结果:观察组鼻咽原发灶及颈淋巴结CR率分别为91.7%及88.9%,较对照组的72.2%和66.7%高(P<0.05),而鼻咽癌伴有头痛和颅神经损害的临床症状缓解的平均剂量观察组比对照组低。结论:多西紫杉醇作为晚期鼻咽癌患者的放疗增效剂具有较好的临床放射增敏作用,其毒副反应患者可接受。
Objective: To observe the small dose of docetaxel weekly administration of locally advanced nasopharyngeal carcinoma in patients with radiosensitization and understand the toxic side effects. Methods: Seventy-two patients with stage Ⅲ and ⅣA nasopharyngeal carcinoma were randomly divided into observation group and control group. The observation group was given docetaxel once a week, 40 m g + radiotherapy. Control group with radiotherapy alone. Radiotherapy methods: Both groups were treated with a 6mV linear accelerator and a low melting point lead block technique. The tumor volume of the primary nasopharyngeal tumor ranged from 6 8 to 7 6 every 7 to 8 weeks. The tumor volume of the cervical lymph node metastasis was 6 ~ 7 weeks 6 0 ~ 7 0. Results: The CR rates of primary nasopharyngeal and cervical lymph nodes in the observation group were 91.7% and 88.9%, respectively, which were significantly higher than those in the control group (72.2% and 66.7%, P <0.05). However, the nasopharyngeal carcinoma with headache and cranial nerve lesion The average dose of clinical symptom relief observation group than the control group. Conclusion: Docetaxel has good clinical radiosensitization as a radiosensitizer for patients with advanced nasopharyngeal carcinoma and its toxicity is acceptable.